Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Chronic rhinitis is affecting more than 200 million people worldwide. Its prevalence is
estimated to be as high as 30% of the Western population. Rhinitis is defined as symptomatic
inflammation of the inner lining of the nose and is characterized by the following symptoms:
rhinorrhea, nasal blockage, nasal itching and/or sneezing. The cut-off point for defining
rhinitis as chronic rhinitis is considered to be persisting symptoms for over more than
twelve weeks Chronic rhinitis can be divided into three major subgroups; based on the
knowledge of the major etiological factor: infectious rhinitis, allergic rhinitis and
non-allergic, non-infectious rhinitis, in literature also referred to as nonallergic
rhinitis. Non-inferiority in efficacy of the two novel treatment regimes i.e. capsaicin nasal
spray 0,01mM (2puffs/nostril/day) during 4 weeks and capsaicin nasal spray 0,001mM
(2puffs/nostril/day) during 4 weeks compared to the current treatment of capsaicin nasal
spray 0,1mM (5/day administered on a single day) with regard to the change from baseline in
VAS for major nasal symptom on week 4.
(Estimated placebo effect is 25%.)